SNP-610
/ Sinew Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
May 01, 2023
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
(clinicaltrials.gov)
- P2 | N=80 | Not yet recruiting | Sponsor: Sinew Pharma Inc. | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024
Trial completion date • Trial primary completion date • Hepatology • Non-alcoholic Steatohepatitis • KRT18
March 09, 2022
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
(clinicaltrials.gov)
- P2 | N=80 | Not yet recruiting | Sponsor: Sinew Pharma Inc. | Trial completion date: Jun 2021 ➔ Dec 2023 | Trial primary completion date: Jun 2021 ➔ Dec 2023
Trial completion date • Trial primary completion date • Hepatology • Non-alcoholic Steatohepatitis • KRT18
April 15, 2018
A Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
(clinicaltrials.gov)
- P2; N=80; Not yet recruiting; Sponsor: Sinew Pharma Inc.; N=44 ➔ 80
Enrollment change • Biosimilar • Immunology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis
March 16, 2018
The Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
(clinicaltrials.gov)
- P2; N=44; Not yet recruiting; Sponsor: Sinew Pharma Inc.
New P2 trial • Biosimilar • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis
March 26, 2018
A Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
(clinicaltrials.gov)
- P2; N=80; Not yet recruiting; Sponsor: Sinew Pharma Inc.
New P2 trial • Biosimilar • Immunology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis
February 23, 2020
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
(clinicaltrials.gov)
- P2; N=80; Not yet recruiting; Sponsor: Sinew Pharma Inc.; Trial completion date: Jun 2020 ➔ Jun 2021; Trial primary completion date: Jun 2020 ➔ Jun 2021
Trial completion date • Trial primary completion date • MRI
December 17, 2019
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
(clinicaltrials.gov)
- P2; N=80; Not yet recruiting; Sponsor: Sinew Pharma Inc.; Trial completion date: Jun 2019 ➔ Jun 2020; Trial primary completion date: Jun 2019 ➔ Jun 2020
Clinical • Trial completion date • Trial primary completion date • MRI
1 to 7
Of
7
Go to page
1